Short answer
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $6M (up 438.7% year over year) with net income of −$41M.
Q1 2026 key financials · XBRL
- Revenue
- $6M
- +438.7% YoY
- Net income
- −$41M
- −38.4% YoY
- Operating margin
- -742.7%
- EPS (diluted)
- −$0.85
- −3.7% YoY
Source: XBRL data from the Dianthus Therapeutics, Inc. /DE/ (DNTH) Q1 2026 10-Q on SEC EDGAR. USD.
Dianthus Therapeutics, Inc. /DE/ Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material risk-factor changes disclosed from December 31, 2025 Form 10-K
- Carried-forward risks may materially harm business, financial condition, results, and growth prospects
- Common-stock market-price decline risk if disclosed adverse events occur
- Additional unknown or currently immaterial risks could harm operations and growth prospects
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Dianthus Therapeutics, Inc. /DE/ quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.